ReviewDiscover oncology2025
Roles, mechanisms, and clinical implications of circHIPK3 in female malignancy: a comprehensive review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CircHIPK3, a recently identified circular RNA, has been implicated in the growth and metastasis of various malignant tumors. This non-coding RNA exhibits aberrant expression patterns in ovarian, cervical, and breast cancers and plays a crucial role in modulating cancer cell proliferation and metastasis. circHIPK3 exerts its regulatory effects by interacting with several microRNAs, including miR-7, miR-338-3p, miR-485-5p, miR-193a, miR-326, miR-1286, and miR-582-3p, and their downstream target genes. Dysregulation of circHIPK3 is associated with poor prognosis in female patients with malignant tumors. Given its significant involvement in these cancers, circHIPK3 is a promising biomarker and therapeutic target. This review synthesizes the current knowledge on the expression patterns, roles, mechanisms, and prognostic relationships of circHIPK3 in female malignant tumors. By elucidating its specific functions, this study aims to provide insights that may inform new strategies for personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.